---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-049570"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:46:40.488394+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners

## Summary
- ATM facility allows sale of up to $75M of common stock from time to time.
- Leerink Partners receives 3.0% commission on gross proceeds; company reimburses certain expenses.
- Net proceeds to fund R&D of product candidates and working capital / general corporate purposes.
- Shares offered under effective S-3 filed Nov 2022; prospectus supplement dated Dec 2, 2024.
- Company not obligated to sell any shares; agreement terminates upon full sale or earlier termination.

## SEC filing metadata
- accession: 0001628280-24-049570
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/0001628280-24-049570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/cntx-20241202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-049570
- JSON: https://secwatch.observer/filing/0001628280-24-049570.json
- Plain text: https://secwatch.observer/filing/0001628280-24-049570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.